CLAIMS

1. A modified release pharmaceutical composition comprising, as active ingredient, a compound of formula (I):



(I)

wherein

R^1 represents C_{1-2} alkyl substituted by one or more fluoro substituents;

R^2 represents hydrogen, hydroxy, methoxy or ethoxy; and

n represents 0, 1 or 2;

or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable diluent or carrier; provided that the formulation may only contain iota-carrageenan and a neutral gelling polymer when the compound of formula (I) is in the form of a salt.

2. A composition as claimed in claim 1 wherein the active ingredient is a salt of:

Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(OMe);

Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(2,6-diF)(OMe); or

Ph(3-Cl)(5-OCH_2CH_2F)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(OMe).

3 A composition as claimed in claim 1 or 2 wherein the active ingredient is a crystalline salt of:

Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(OMe);

Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(2,6-diF)(OMe); or

Ph(3-Cl)(5-OCH_2CH_2F)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(OMe).

4. A composition as claimed in any one of claims 1, 2 or 3 wherein the active ingredient is an ethanesulfonic acid, *n*-propanesulfonic acid, benzenesulfonic acid,

1,5-naphthalenedisulfonic acid, or n-butanesulfonic acid addition salt of Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(OMe) or Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(2,6-diF)(OMe).

5. A composition as claimed in any one of claims 1 to 4 wherein the active ingredient is Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(OMe), benzene-sulfonic acid salt, characterised by an X-ray powder diffraction pattern characterised by peaks with d-values at 5.9, 4.73, 4.09 and 4.08Å.

6. A composition as claimed in any one of claims 1 to 4 wherein the active ingredient is Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(2,6-diF)(OMe), hemi-1,5-naphthalenedisulfonic acid salt, characterised by an X-ray powder diffraction pattern characterised by peaks with d-values at 18.3, 9.1, 5.6, 5.5, 4.13, 4.02, 3.86, 3.69 and 3.63Å.

7. A composition as claimed in any one of claims 1 to 6 wherein the composition comprises a gelling matrix.

8. A composition as claimed in claim 7 wherein the matrix comprises HPMC.

9. A composition as claimed in claim 7 or 8 wherein the matrix comprises iota-carrageenan.

10. A composition as claimed in claim 7 wherein the matrix comprises SDS.

11. The use of a formulation as claimed in claim 1 as a medicament.

12. The use of a formulation as claimed in claim 1 in the manufacture of a medicament for the treatment of a cardiovascular disorder.

13. A method of treating a cardiovascular disorder in a patient suffering from, or at risk of, said disorder, which comprises administering to the patient a therapeutically effective amount of a pharmaceutical formulation as claimed in claim 1.